Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2012 1
2013 2
2014 1
2017 2
2018 1
2021 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

8 results

Results by year

Filters applied: . Clear all
Page 1
PAM-50 predicts local recurrence after breast cancer surgery in postmenopausal patients with ER+/HER2- disease: results from 1204 patients in the randomized ABCSG-8 trial.
Fitzal F, Filipits M, Fesl C, Rudas M, Greil R, Balic M, Moinfar F, Herz W, Dubsky P, Bartsch R, Ferree S, Schaper C, Gnant M; Austrian Breast and Colorectal Cancer Study Group (ABCSG). Fitzal F, et al. Br J Surg. 2021 Apr 5;108(3):308-314. doi: 10.1093/bjs/znaa089. Br J Surg. 2021. PMID: 33608712 Free PMC article. Clinical Trial.
A prospective, multicenter pilot study to investigate the feasibility and safety of a 1-year controlled exercise training after adjuvant chemotherapy in colorectal cancer patients.
Piringer G, Fridrik M, Fridrik A, Leiherer A, Zabernigg A, Greil R, Eisterer W, Tschmelitsch J, Lang A, Frantal S, Burgstaller S, Gnant M, Thaler J; Austrian Breast and Colorectal Cancer Study Group (ABCSG). Piringer G, et al. Support Care Cancer. 2018 Apr;26(4):1345-1352. doi: 10.1007/s00520-017-3961-8. Epub 2017 Nov 22. Support Care Cancer. 2018. PMID: 29168033 Clinical Trial.
Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy.
Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Kainberger F, Kässmann H, Piswanger-Sölkner JC, Seifert M, Ploner F, Menzel C, Dubsky P, Fitzal F, Bjelic-Radisic V, Steger G, Greil R, Marth C, Kubista E, Samonigg H, Wohlmuth P, Mittlböck M, Jakesz R; Austrian Breast and Colorectal Cancer Study Group (ABCSG). Gnant M, et al. Lancet Oncol. 2008 Sep;9(9):840-9. doi: 10.1016/S1470-2045(08)70204-3. Epub 2008 Aug 19. Lancet Oncol. 2008. PMID: 18718815 Clinical Trial.
The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients.
Dubsky P, Brase JC, Jakesz R, Rudas M, Singer CF, Greil R, Dietze O, Luisser I, Klug E, Sedivy R, Bachner M, Mayr D, Schmidt M, Gehrmann MC, Petry C, Weber KE, Fisch K, Kronenwett R, Gnant M, Filipits M; Austrian Breast and Colorectal Cancer Study Group (ABCSG). Dubsky P, et al. Br J Cancer. 2013 Dec 10;109(12):2959-64. doi: 10.1038/bjc.2013.671. Epub 2013 Oct 24. Br J Cancer. 2013. PMID: 24157828 Free PMC article.
Preoperative treatment with capecitabine, cetuximab and radiotherapy for primary locally advanced rectal cancer--a phase II clinical trial.
Eisterer W, De Vries A, Öfner D, Rabl H, Koplmüller R, Greil R, Tschmelitsch J, Schmid R, Kapp K, Lukas P, Sedlmayer F, Höfler G, Gnant M, Thaler J; Austrian Breast and Colorectal Cancer Study Group (ABCSG). Eisterer W, et al. Anticancer Res. 2014 Nov;34(11):6767-73. Anticancer Res. 2014. PMID: 25368289 Clinical Trial.
EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer.
Dubsky P, Filipits M, Jakesz R, Rudas M, Singer CF, Greil R, Dietze O, Luisser I, Klug E, Sedivy R, Bachner M, Mayr D, Schmidt M, Gehrmann MC, Petry C, Weber KE, Kronenwett R, Brase JC, Gnant M; Austrian Breast and Colorectal Cancer Study Group (ABCSG). Dubsky P, et al. Ann Oncol. 2013 Mar;24(3):640-7. doi: 10.1093/annonc/mds334. Epub 2012 Oct 3. Ann Oncol. 2013. PMID: 23035151 Free PMC article.
Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX.
Emile JF, Julié C, Le Malicot K, Lepage C, Tabernero J, Mini E, Folprecht G, Van Laethem JL, Dimet S, Boulagnon-Rombi C, Allard MA, Penault-Llorca F, Bennouna J, Laurent-Puig P, Taieb J; PETACC8 Study Investigators; Austrian Breast and Colorectal cancer Study Group (ABCSG); Belgian Group of Digestive Oncology (BGDO); Lone Nørgård Petersen; Fédération Francophone de Cancérologie Digestive (FFCD); Fédération Nationale des Centres de Lutte Contre le Cancer (UNICANCER); Fédération Nationale des Centres de Lutte Contre le Cancer Association Européenne de Recherche en Oncologie (AERO); Arbeitsgemeinschaft Internistische Onkologie (AIO); Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente (GISCAD); Gruppo Oncologico dell'Italia Meridionale (GOIM); Istituto Oncologico Romagnolo (IOR); Gruppo Cooperativo Chirurgico Italiano (GOCCI); Gruppo Oncologico Nord Ovest (GONO); Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC); Gruppo Cooperativo do Cancro Digestivo da Associação Portuguesa de Investigação Oncológica (GCCD, APIO); Grupo Español para el Tratamiento de los Tumores Digestivos (TTD); John Allen Bridgewater. Emile JF, et al. Eur J Cancer. 2017 Sep;82:16-24. doi: 10.1016/j.ejca.2017.04.025. Epub 2017 Jun 23. Eur J Cancer. 2017. PMID: 28651158